<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36962089</PMID><DateRevised><Year>2023</Year><Month>11</Month><Day>01</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2767-3375</ISSN><JournalIssue CitedMedium="Internet"><Volume>1</Volume><Issue>10</Issue><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>PLOS global public health</Title><ISOAbbreviation>PLOS Glob Public Health</ISOAbbreviation></Journal><ArticleTitle>Vaccine rollout strategies: The case for vaccinating essential workers early.</ArticleTitle><Pagination><StartPage>e0000020</StartPage><MedlinePgn>e0000020</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0000020</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pgph.0000020</ELocationID><Abstract><AbstractText>In vaccination campaigns against COVID-19, many jurisdictions are using age-based rollout strategies, reflecting the much higher risk of severe outcomes of infection in older groups. In the wake of growing evidence that approved vaccines are effective at preventing not only adverse outcomes, but also infection, we show that such strategies are less effective than strategies that prioritize essential workers. This conclusion holds across numerous outcomes, including cases, hospitalizations, Long COVID (cases with symptoms lasting longer than 28 days), deaths and net monetary benefit. Our analysis holds in regions where the vaccine supply is limited, and rollout is prolonged for several months. In such a setting with a population of 5M, we estimate that vaccinating essential workers sooner prevents over 200,000 infections, over 600 deaths, and produces a net monetary benefit of over $500M.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2021 Mulberry et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mulberry</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-1465-8001</Identifier><AffiliationInfo><Affiliation>Department of Mathematics, Simon Fraser University, Burnaby, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tupper</LastName><ForeName>Paul</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-4340-4481</Identifier><AffiliationInfo><Affiliation>Department of Mathematics, Simon Fraser University, Burnaby, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirwin</LastName><ForeName>Erin</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-6957-7236</Identifier><AffiliationInfo><Affiliation>Institute of Health Economics, Alberta, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Health Organisation, Policy, and Economics, School of Health Sciences, University of Manchester, Manchester, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCabe</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-5728-4129</Identifier><AffiliationInfo><Affiliation>Institute of Health Economics, Alberta, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine and Dentistry, Department of Emergency Medicine, University of Alberta, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colijn</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-6097-6708</Identifier><AffiliationInfo><Affiliation>Department of Mathematics, Simon Fraser University, Burnaby, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>10</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLOS Glob Public Health</MedlineTA><NlmUniqueID>9918283779606676</NlmUniqueID><ISSNLinking>2767-3375</ISSNLinking></MedlineJournalInfo><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>5</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>9</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>24</Day><Hour>17</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>13</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>13</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>10</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36962089</ArticleId><ArticleId IdType="pmc">PMC10021761</ArticleId><ArticleId IdType="doi">10.1371/journal.pgph.0000020</ArticleId><ArticleId IdType="pii">PGPH-D-21-00035</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zimmer C, Corum J, Wee SL. Coronavirus Vaccine Tracker. The New York Times. 2021. Feb.</Citation></Reference><Reference><Citation>Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al.. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England Journal of Medicine. 2020. doi: 10.1056/NEJMoa2035389</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035389</ArticleId><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, et al.. The Advisory Committee on Immunization Practices&#x2019; Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine&#x2014;United States, December 2020. MMWR Morb Mortal Wkly Rep. 2020. Dec;69(50):1922&#x2013;1924. doi: 10.15585/mmwr.mm6950e2</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6950e2</ArticleId><ArticleId IdType="pmc">PMC7745957</ArticleId><ArticleId IdType="pubmed">33332292</ArticleId></ArticleIdList></Reference><Reference><Citation>Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al.. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021. Jan;397(10269):99&#x2013;111. doi: 10.1016/S0140-6736(20)32661-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32661-1</ArticleId><ArticleId IdType="pmc">PMC7723445</ArticleId><ArticleId IdType="pubmed">33306989</ArticleId></ArticleIdList></Reference><Reference><Citation>Caddy SL. Coronavirus: few vaccines prevent infection&#x2013;here&#x2019;s why that&#x2019;s not a problem. The Conversation. 2021. Jan.</Citation></Reference><Reference><Citation>ModernaTX I. mRNA-1273: Sponsor Briefing Document Addendum;. Vaccines and Related Biological Products Advisory Committee. https://www.cdc.gov/me-cfs/. Available from: https://www.fda.gov/media/144453/download.</Citation></Reference><Reference><Citation>Mitnick J, Regalado A. A leaked report shows Pfizer&#x2019;s vaccine is conquering covid-19 in its largest real-world test.; 2021. https://www.technologyreview.com/2021/02/19/1019264/a-leaked-report-pfizers-vaccine-conquering-covid-19-in-its-largest-real-w.</Citation></Reference><Reference><Citation>Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A, et al.. Effectiveness of BNT162b2 mRNA Vaccine Against Infection and COVID-19 Vaccine Coverage in Healthcare Workers in England, Multicentre Prospective Cohort Study (the SIREN Study); 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8064668</ArticleId><ArticleId IdType="pubmed">33901423</ArticleId></ArticleIdList></Reference><Reference><Citation>Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine.</Citation></Reference><Reference><Citation>Emary KRW, Golubchik T, Aley PK, Ariani CV, Angus BJ, Bibi S, et al.. Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7); 2021.</Citation></Reference><Reference><Citation>Petter E, Mor O, Zuckerman N, Oz-Levi D, Younger A, Aran D, et al.. Initial real world evidence for lower viral load of individuals who have been vaccinated by BNT162b2; 2021.</Citation></Reference><Reference><Citation>Levine-Tiefenbrun M, Yelin I, Katz R, Herzel E, Golan Z, Schreiber L, et al.. Decreased SARSCoV-2 viral load following vaccination; 2021. doi: 10.1038/s41591-021-01316-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01316-7</ArticleId><ArticleId IdType="pubmed">33782619</ArticleId></ArticleIdList></Reference><Reference><Citation>Mallapaty S. The coronavirus is most deadly if you are older and male&#x2014;new data reveal the risks. Nature. 2020. Sep;585(7823):16&#x2013;17. doi: 10.1038/d41586-020-02483-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-020-02483-2</ArticleId><ArticleId IdType="pubmed">32860026</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong E. Long-Haulers Are Redefining COVID-19. The Atlantic. 2020. Aug.</Citation></Reference><Reference><Citation>Editorial. Long COVID: let patients help define long-lasting COVID symptoms. Nature. 2020;586(170). doi: 10.1038/d41586-020-02796-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-020-02796-2</ArticleId><ArticleId IdType="pubmed">33029005</ArticleId></ArticleIdList></Reference><Reference><Citation>Logue JK, Franko NM, McCulloch DJ, McDonald D, Magedson A, Wolf CR, et al.. Sequelae in Adults at 6 Months After COVID-19 Infection. JAMA Netw Open. 2021. Feb;4(2):e210830. doi: 10.1001/jamanetworkopen.2021.0830</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.0830</ArticleId><ArticleId IdType="pmc">PMC7896197</ArticleId><ArticleId IdType="pubmed">33606031</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam MHB, Wing YK, Yu MWM, Leung CM, Ma RC, Kong AP, et al.. Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors: long-term follow-up. Archives of internal medicine. 2009;169(22):2142&#x2013;2147. doi: 10.1001/archinternmed.2009.384</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinternmed.2009.384</ArticleId><ArticleId IdType="pubmed">20008700</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention. Myalgic encephalomyelitis/chronic fatigue syndrome;. Accessed: 2021-02-14. https://www.cdc.gov/me-cfs/.</Citation></Reference><Reference><Citation>Office for National Statistics (UK). The prevalence of long COVID symptoms and COVID-19 complications; Accessed: 2021-2-17. https://www.ons.gov.uk/news/statementsandletters/theprevalenceoflongcovidsymptomsandcovid19complications.</Citation></Reference><Reference><Citation>Rubino F, Amiel SA, Zimmet P, Alberti G, Bornstein S, Eckel RH, et al.. New-Onset Diabetes in Covid-19. N Engl J Med. 2020. Aug;383(8):789&#x2013;790. doi: 10.1056/NEJMc2018688</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2018688</ArticleId><ArticleId IdType="pmc">PMC7304415</ArticleId><ArticleId IdType="pubmed">32530585</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto DS. Coronavirus disease 2019 (COVID-19): Myocardial infarction and other coronary artery disease issues;. Accessed: 2021-2-17. https://www.uptodate.com/contents/coronavirus-disease-2019-covid-19-myocardial-infarction-and-other-coronar.</Citation></Reference><Reference><Citation>Rismanbaf A, Zarei S. Liver and Kidney Injuries in COVID-19 and Their Effects on Drug Therapy; a Letter to Editor. Arch Acad Emerg Med. 2020. Mar;8(1):e17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7075271</ArticleId><ArticleId IdType="pubmed">32185369</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. Six-month Neurological and Psychiatric Outcomes in 236,379 Survivors of COVID-19. medRxiv. 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8023694</ArticleId><ArticleId IdType="pubmed">33836148</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu J, Gong E, Zhang B, Zheng J, Gao Z, Zhong Y, et al.. Multiple organ infection and the pathogenesis of SARS. J Exp Med. 2005. Aug;202(3):415&#x2013;424. doi: 10.1084/jem.20050828</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20050828</ArticleId><ArticleId IdType="pmc">PMC2213088</ArticleId><ArticleId IdType="pubmed">16043521</ArticleId></ArticleIdList></Reference><Reference><Citation>Souza INO, Barros-Aragao FGQ, Frost PS, Figueiredo CP, Clarke JR. Late Neurological Consequences of Zika Virus Infection: Risk Factors and Pharmaceutical Approaches. Pharmaceuticals. 2019. Apr;12(2). doi: 10.3390/ph12020060</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph12020060</ArticleId><ArticleId IdType="pmc">PMC6631207</ArticleId><ArticleId IdType="pubmed">30999590</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao-Lormeau VM, Blake A, Mons S, Lastere S, Roche C, Vanhomwegen J, et al.. Guillain-Barr&#xe9; Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet. 2016. Apr;387(10027):1531&#x2013;1539. doi: 10.1016/S0140-6736(16)00562-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(16)00562-6</ArticleId><ArticleId IdType="pmc">PMC5444521</ArticleId><ArticleId IdType="pubmed">26948433</ArticleId></ArticleIdList></Reference><Reference><Citation>Spencer CA. &#x2018;Long-haul&#x2019; covid-19 complications are real. I faced similar problems after surviving Ebola. The Washington Post. 2020. Sep.</Citation></Reference><Reference><Citation>Bubar KM, Reinholt K, Kissler SM, Lipsitch M, Cobey S, Grad YH, et al.. Model-informed COVID-19 vaccine prioritization strategies by age and serostatus. Science. 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7963218</ArticleId><ArticleId IdType="pubmed">33479118</ArticleId></ArticleIdList></Reference><Reference><Citation>Matrajt L, Eaton J, Leung T, Brown ER. Vaccine optimization for COVID-19: Who to vaccinate first? Sci Adv. 2020. Feb;7(6). doi: 10.1126/sciadv.abf1374</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abf1374</ArticleId><ArticleId IdType="pmc">PMC8128110</ArticleId><ArticleId IdType="pubmed">33536223</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, Hoops S, Marathe A, Mortveit H, Lewis B, Venkatramanan S, et al.. Prioritizing allocation of COVID-19 vaccines based on social contacts increases vaccination effectiveness. medRxiv. 2021. Available from: https://www.medrxiv.org/content/early/2021/02/06/2021.02.04.21251012. doi: 10.1101/2021.02.04.21251012
</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.02.04.21251012</ArticleId><ArticleId IdType="pmc">PMC7872370</ArticleId><ArticleId IdType="pubmed">33564778</ArticleId></ArticleIdList></Reference><Reference><Citation>Jentsch PC, Anand M, Bauch CT. Prioritising COVID-19 vaccination in changing social and epidemiological landscapes: a mathematical modelling study. Lancet Infect Dis. 2021. Mar. doi: 10.1016/S1473-3099(21)00057-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00057-8</ArticleId><ArticleId IdType="pmc">PMC8012029</ArticleId><ArticleId IdType="pubmed">33811817</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez J, Pat&#xf3;n M, Acu&#xf1;a JM. COVID-19 vaccination rate and protection attitudes can determine the best prioritisation strategy to reduce fatalities. medRxiv. 2021. Available from: https://www.medrxiv.org/content/early/2021/02/10/2020. 10.12.20211094.</Citation></Reference><Reference><Citation>Buckner JH, Chowell G, Springborn MR. Dynamic prioritization of COVID-19 vaccines when social distancing is limited for essential workers. Proc Natl Acad Sci U S A. 2021. Apr;118(16). doi: 10.1073/pnas.2025786118</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2025786118</ArticleId><ArticleId IdType="pmc">PMC8072365</ArticleId><ArticleId IdType="pubmed">33811185</ArticleId></ArticleIdList></Reference><Reference><Citation>Babus A, Das S, Lee S. The Optimal Allocation of Covid-19 Vaccines; 2020. Available from: https://www.medrxiv.org/content/early/2020/12/03/2020. 07.22.20160143. doi: 10.1213/XAA.0000000000001133
</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/XAA.0000000000001133</ArticleId><ArticleId IdType="pmc">PMC9886398</ArticleId><ArticleId IdType="pubmed">36741504</ArticleId></ArticleIdList></Reference><Reference><Citation>Emergency Management BC, Government Communications and Public Engagement. COVID-19 essential services;. Accessed: 2021-2-21. https://www2.gov.bc.ca/gov/content/safety/emergency-preparedness-response-recovery/covid-19-provincial-support/essential-services-covid-19.</Citation></Reference><Reference><Citation>Mayo Clinic. COVID-19 variants: What&#x2019;s the concern?; 2021. Accessed: 2021-2-23. https://www.mayoclinic.org/diseases-conditions/coronavirus/expert-answers/covid-variant/faq-20505779.</Citation></Reference><Reference><Citation>COVID-19 Immunization Plan;. Accessed: 2021-1-22. https://www2.gov.bc.ca/gov/content/covid-19/vaccine/plan#phases.</Citation></Reference><Reference><Citation>Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull. 2010. Oct;96:5&#x2013;21. doi: 10.1093/bmb/ldq033</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bmb/ldq033</ArticleId><ArticleId IdType="pubmed">21037243</ArticleId></ArticleIdList></Reference><Reference><Citation>Briggs AH, Goldstein DA, Kirwin E, Meacock R, Pandya A, Vanness DJ, et al.. Estimating (quality-adjusted) life-year losses associated with deaths: With application to COVID-19. Health Economics. 2020. doi: 10.1002/hec.4208</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hec.4208</ArticleId><ArticleId IdType="pubmed">33368853</ArticleId></ArticleIdList></Reference><Reference><Citation>Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making. 1998. Apr;18(2 Suppl):S68&#x2013;80. doi: 10.1177/0272989X98018002S09</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0272989X98018002S09</ArticleId><ArticleId IdType="pubmed">9566468</ArticleId></ArticleIdList></Reference><Reference><Citation>Government Communications, Engagement P. COVID-19 Immunization Plan;. Accessed: 2021-2-22. https://www2.gov.bc.ca/gov/content/safety/emergency-preparedness-response-recovery/covid-19-provincial-support/vaccines.</Citation></Reference><Reference><Citation>Massachusetts&#x2019; COVID-19 vaccination phases;. Accessed: 2021-2-22. https://www.mass.gov/info-details/massachusetts-covid-19-vaccination-phases.</Citation></Reference><Reference><Citation>Australian Government Department of Health. When will I get a COVID-19 vaccine?; 2020. Accessed: 2021-2-22. https://www.health.gov.au/initiatives-and-programs/covid-19-vaccines/getting-vaccinated-for-covid-19/when-will-i-get-a-covid-19-vaccine.</Citation></Reference><Reference><Citation>Centre for Disease Control. CDC&#x2019;s COVID-19 Vaccine Rollout Recommendations; 2021. Accessed: 2021-3-1. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations.html.</Citation></Reference><Reference><Citation>Rao A, Ma H, Moloney G, Kwong JC, Juni P, Sander B, et al..&#xa8; A disproportionate epidemic: COVID-19 cases and deaths among essential workers in Toronto, Canada. medRxiv. 2021. Available from: https://www.medrxiv.org/content/early/2021/03/11/2021.02.15.21251572. doi: 10.1016/j.annepidem.2021.07.010
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.annepidem.2021.07.010</ArticleId><ArticleId IdType="pmc">PMC8435380</ArticleId><ArticleId IdType="pubmed">34314847</ArticleId></ArticleIdList></Reference><Reference><Citation>A timeline of UK lockdown measures since the pandemic began;. Accessed: 2021-3-19. https://www.expressandstar.com/news/uk-news/2021/01/04/a-timeline-of-uk-lockdown-measures-since-the-pandemic-began/.</Citation></Reference><Reference><Citation>Washington NL, Gangavarapu K, Zeller M, Bolze A, Cirulli ET, Schiabor Barrett KM, et al.. Genomic epidemiology identifies emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States. medRxiv. 2021. Feb. doi: 10.1101/2021.02.06.21251159</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.02.06.21251159</ArticleId><ArticleId IdType="pmc">PMC8009040</ArticleId><ArticleId IdType="pubmed">33861950</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown KA, Gubbay J, Hopkins J, Patel S, Buchan SA, Daneman N, et al.. Rapid Rise of S-Gene Target Failure and the UK variant B.1.1.7 among COVID-19 isolates in the Greater Toronto Area, Canada; 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8033504</ArticleId><ArticleId IdType="pubmed">33830171</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO&#x2014;SARS-CoV-2 Variants. World Health Organization; 2021. urlhttps://www.who.int/csr/don/31-december-2020-sars-cov2-variants/en/.</Citation></Reference><Reference><Citation>Ontario&#x2019;s COVID-19 vaccination plan;. Accessed: 2021-07-11. https://covid-19.ontario.ca/ontarios-covid-19-vaccination-plan.</Citation></Reference><Reference><Citation>Front-line workers prioritized as COVID-19 vaccine rollout accelerates;. Accessed: 2021-07-11. https://news.gov.bc.ca/releases/2021PREM0021-000504.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>